Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation
Glucagon-like peptide-1 receptor agonist therapy using semaglutide is associated with a reduced risk of AF recurrence in obese patients undergoing AF catheter ablation, indicating its potential as an adjunctive treatment. Further studies are needed to confirm these findings and elucidate the effects of GLP-1RA on AF recurrence.
Authors
- Gabriele Negro (ORCID: https://orcid.org/0000-0003-1531-3504)
- Žarko Ćalović (ORCID: https://orcid.org/0000-0002-3267-9850)
- CARLO PAPPONE
- Antonio Boccellino (ORCID: https://orcid.org/0000-0003-3406-2675)
- Antonio Izzo (ORCID: https://orcid.org/0000-0001-5018-3835)
- Cristiano Ciaccio
- Roberto Rondine (ORCID: https://orcid.org/0000-0002-7143-8902)
- Alessandro Fuga
- Luigi Giannelli (ORCID: https://orcid.org/0000-0001-8141-9476)
- Davide Antonio Morciano (ORCID: https://orcid.org/0009-0001-7669-4139)
- Alessia Vuturo
- Raffaele Salerno
- Arianna Garbelli
- Luigi Anastasia
- Marco Ballarotto
- Vincenzo Maiolo
Institutions
- Vita-Salute San Raffaele University (IT)
- IRCCS Policlinico San Donato (IT)
- Mylan (South Africa) (ZA)
Publication Details
- Journal
- EP Europace
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1093/europace/euag018
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00